Breaking News, Trials & Filings

FDA Approves Expanded Indication for Merck’s ERVEBO

Now indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older.

Merck received approval from the U.S. FDA for an expanded indication for ERVEBO, which is now indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older. The vaccine was previously approved for use in individuals 18 years of age and older. ERVEBO does not protect against other species of Ebolavirus or Marburgvirus and the duration of protection conferred by ERVEBO is unknown. The effectiveness of the vaccine when administered concurrently with an...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters